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Abstract 
The intricate and multifactorial nature of Alzheimer´s disease (AD) requires the 
development of compounds able to hit different pathophysiological targets, such as 
cholinergic dysfunction, deposits of amyloid-β peptide (Aβ) and metal dyshomeostasis. 
In order to continue the search for new anti-AD drugs, a design strategy was followed 
based on repositioning donepezil (DNP), by attaching a benzylpiperidine mimetic of DNP 
moiety at different (ortho, para) attachment points of a hydroxyphenyl-benzimidazole 
(BIM) chelating unit. Herein, two compounds (1 and 2) are compared in terms of their 
potential multiple properties: both present good AChE inhibition (low micromolar range) 
and are moderate/good inhibitors of Aβ self- and Cu-mediated aggregation; although 
compound 1 has a higher chelating capacity towards Cu2+ (pCu  = 14.3, pZn = 6.4, pH 
7.4, CL/CM = 10, CM = 10−6 M) than 2 (pCu = 10.7, pZn = 6.3), attributed to its ability to 
establish a tridentate (N,O,O) coordination to the metal ion. Both compounds are eligible 
as drug candidates for oral administration but compound 1 shows improved 
neuroprotective role by completely preventing Aβ-induced cell toxicity. 
 
1. Introduction 
 
Alzheimer's disease (AD) is one of the most common and devastating age-dependent 
neurodegenerative disorders and its prevalence is expected to enormously increase in the 
coming years because of the population growth and ageing [1]. Hence, there has been a 
worldwide intensive research aimed to understand and find treatment for AD, but no cure 
has been found so far [2,3]. Currently approved AD therapeutics are only able to attenuate 
the dementia symptoms by compensating the cholinergic deficit, as the 
acetylcholinesterase (AChE) inhibitors (tacrine, donepezil, rivastigmine, galantamine) or 
the glutamate N-methyl D-aspartate (NMDA) receptor antagonist (memantine) [4]. 
The recognized multifactorial nature and consequent complexity of AD are believed to 
account for the absence of disease-modifying drugs. In fact, the formation of misfolded 
protein aggregates, namely β-amyloid (Aβ) plaques (a prominent hallmark of AD), 
dyshomeostasis of metal ions and oxidative stress are among the many factors that are 
implicated in the trigger and progression of AD [5]. Furthermore, although Aβ 
imbalance has been considered to be a causative agent in AD, high levels of metals (e.g. 
Fe, Cu, Zn) have been found in the Aβ plaques of AD brains and, in particular, Cu and 
Zn bind to Aβ peptides, promoting their aggregation, while redox active metal ions (e.g. 
Cu, Fe) promote overproduction of reactive oxygen species (ROS) that can damage 
biomolecules [6–8]. Therefore, to address the multiple pathological factors and their 
potential interconnections in AD pathogenesis, in the last decade there has been a change 
of paradigm from singletarget drugs towards multi-target drugs as chemical entities (the 
so called multi-target ligands) able to address multiple biological targets involved in the 
disease, aimed to get possible therapeutic answers [9–11]. 
 
 
Fig 1. DNP and DNP-BIM hybrids (1 and 2), chelators with different attachment points 
between the benzylpiperidine and the BIM moieties. 
 
In recent years, several research groups, including ours, have developed hybrid 
compounds, via a rational structure-based methodology which integrates a moiety with 
capacity for AChE inhibition with a framework able to interact with Aβ and also possess 
metal cheating capacity, so that to associate the symptom treatment with disease 
modifying roles, namely to inhibit the Aβ self- and metal-induced aggregation and to 
attenuate the metal-promoted ROS formation [12–16]. Herein we report the synthesis, 
physico-chemical and biological evaluation as well as molecular modeling of a new 
donepezil-hydroxyphenylbenzimidazole (DNP-BIM) chelating hybrid (1) (Fig. 1). This 
compound results from a structural modification of a recently reported positional isomer 
DNP hybrid (2) [17], for the sake of increasing ligand denticity and thus improving the 
metal chelating capacity as well as the control/modulation of interconnected multiple 
pathological features of AD, namely those that could arise from the synergy of its metal 
chelation and Aβ interaction properties. 
2. Experimental  
2.1. Chemistry 
2.1.1. General methods and materials 
Analytical grade reagents were purchased and used as supplied. Solvents were dried 
according to standard methods [1]. The chemical reactions were monitored by TLC using 
alumina plates coated with silica gel 60 F254 (Merck). Column chromatography 
separations were performed on silica gel Merck 230-400 mesh (Geduran Si 60). The 
melting points (m.p.) were measured with a Leica Galen III hot stage apparatus and are 
uncorrected. The 1H- and 13C-NMR spectra were recorded on Bruker AVANCE III 
spectrometers at 300 and 400 MHz, respectively. Chemical shifts (δ) are reported in ppm 
from the standard internal reference tetramethylsilane (TMS). The following 
abbreviations are used: s = singlet, d = doublet, t = triplet, m = multiplet. Mass spectra 
(ESI-MS) were performed on a 500 MS LC Ion Trap (Varian Inc., Palo Alto, CA, USA) 
mass spectrometer equipped with an ESI ion source, operated in the positive or negative 
ion mode. For the target compounds, the elemental analyses were performed on a Fisons 
EA1108 CHNS/O instrument at LAIST and were within the limit of ± 0.4%. The 
electronic spectra were recorded with a Perkin Elmer Lambda 35 spectrophotometer, 
using thermostated 1-cm path length cells and the fluorescence measurements were 
performed with a Spectramax Gemini EM (Molecular Devices) fluorimeter.  
2.1.2. Synthesis of compound 1 
2.1.2.1. 2-((1-Benzylpiperidin-4-yl)methyl)isoindoline-1,3-dione (1a) 
Phthalic acid anhydride (1 eq) and 4-(aminomethyl)piperidine (1 eq) were heated at 160 
°C for 4 h. The resulting dark brown solid was mixed with K2CO3 (6.6 eq), triethylamine 
(1.4 eq) and benzyl chloride (2.3 eq) and refluxed in acetonitrile for 3 h. Then, the mixture 
was cooled at rt, added to water, and extracted with ethyl acetate (three times). The 
organic layers were collected, dried over sodium sulphate anhydrous, and concentrated 
under reduced pressure. The crude was purified through chromatography column (eluent: 
ACN/H2O/NH4OH 92:8:0.1), affording a white solid ( = 29%); M.P. = 130 °C. 1H NMR 
(300 MHz, MeOD-d4), δ (ppm): 1.37 (m, 2H, Pip), 1.67 (d, 2H, J = 12.0 Hz, Pip), 1.80 
(m, 1H, Pip), 2.02 (td, 2H, J = 12.0 Hz, Pip), 2.91 (d, 2H, J = 12.0 Hz, Pip), 3.51 (s, 2H, 
NCH2Ph), 3.58 (d, 2H, J = 12.0 Hz, NCH2CH), 7.34-7.29 (m, 5H, Ph), 7.89-7.79 (m, 4H, 
Phth); m/z (ESI-MS): 335.00 (M+H)+.  
 
2.1.2.2. (1-Benzylpiperidin-4-yl)methanamine (1b) 
2-((1-Benzylpiperidin-4-yl)methyl)isoindoline-1,3-dione (1 eq) and hydrazine 
monohydrate (6 eq) were dissolved in absolute ethanol and warmed at 60 °C for 3 h. The 
reaction mixture was then filtered and concentrated under reduced pressure. The residue 
was dissolved in dichloromethane, washed with brine (three times), dried over anhydrous 
sodium sulphate, and concentrated under reduced pressure obtaining a pure yellow-
orange oil ( = 30.5%). 1H NMR (300 MHz, MeOD-d4), δ (ppm): 1.01-1.21 (m, 2H, Pip), 
1.64 (d, 2H, J = 12.0 Hz, Pip), 1.86 (t, 1H, J = 12.0 Hz, Pip), 2.40 (d, 2H, J = 12.0 Hz, 
Pip), 2.78 (d, 2H, J = 12.0 Hz, NCH2CH) 2.91 (d, 2H, J = 12.0 Hz, Pip), 3.51 (s, 2H, 
NCH2Ph), 7.34-7.19 (m, 5H, Ph) 
 
2.1.2.3. 2-(2-Hydroxyphenyl)-1H-benzo[d]imidazole-4-carboxylic acid (1c) 
To a solution of salicylaldehyde (1 eq) and Na2S2O5 (1.2 eq) in the green solvent 
(glycerol/choline chloride (2:1)) was added the 2,3-diaminobenzoic acid (1 eq). The 
mixture was heated at 50 °C for 30 min. Then, the mixture was cooled at rt, added to 
water and filtrated. The afforded solid was washed with water and then dichloromethane 
and then purified by recristallisation in EtOAc and MeOH. The title compound was 
obtained as a purple solid ( =25.2%), m.p. >300°C. 1H NMR (300 MHz, MeOD-d4), δ 
(ppm): 7.08 (d, 2H, J = 8.0 Hz, BIM); 7.42 (m, 2H, J = 8.0 Hz, BIM), 7.96 (t, 2H, J = 8.0 
Hz, BIM), 8.25 (d, 1H, BIM); m/z (ESI-MS): 253 (M-1)+, 255.00 (M+1)+. 
2.1.2.3. N-((1-benzylpiperidin-4-yl)methyl)-2-(2-hydroxyphenyl)-1H-
benzo[d]imidazole-4-carboxamide (1) 
To a solution of the 2-(2-hydroxyphenyl)-1H-benzo[d]imidazole-4-carboxylic acid (1 eq, 
1c) and (1-benzylpiperidin-4-yl)methanamine (1 eq, 2b),  in dry DMF, was added N-
hydroxysuccinimide (1 eq) and DCC (1 eq), and the reaction mixture was left stirring for 
24 h at r.t.. Then the precipitate obtained (urea) was filtered off and the liquid phase was 
diluted with ethyl acetate and washed with brine (3 times), dried over anhydrous sodium 
sulfate, concentrated under reduced pressure and purified by recrystallization in EtOAc 
affording a yellow solid ( = 24.2%); m.p. = 192-193 °C. 1H RMN (300 MHz, MeOD-
d4), δ (ppm): 1.75-1.95 (m, 5H, Pip), 2.17 (t, 2H, J = 12 Hz, Pip), 3.02 (d, 2H, J = 12 Hz, 
Pip), 3.49 (d, 2H, J = 6 Hz, CH2NCO), 3.60 (s, 2H, CH2Ph), 7.00-7.08 (m, 2H, Ph), 7.28-
7.42 (m, 7H, Ph), 7.79 (d, 1H, J = 9 Hz, BIM), 7.89 (d, 1H, J = 8 Hz, BIM), 8.16 (d, 1H, 
J = 9 Hz, BIM). 13C RMN (100 MHz, MeOD-d4), δ (ppm): 29.25, 33.35, 44.31, 52.77, 
62.44, 116.65, 119.45, 119.54, 122.13, 127.18, 127.59, 127.84, 129.50, 129.59, 131.84, 
131.91, 135.91, 136.56, 139.11, 139.33, 151.40, 157.44, 161.38; m/z (ESI-MS): 439.00 
(M-1), 441.00 (M+1). 
 
2.2. Molecular modeling for ligand-AChE docking 
To perform the ligand-enzyme docking studies, the X-ray crystallographic structure of 
Torpedo californica-AChE (TcAChE) complexed with an inhibitor (donepezil, Dnp) was 
taken from RCSB Protein Data Bank (PDB entry 1 EVE) [2], in order to be used as 
enzyme model. This structure was chosen because of the similarity between the original 
inhibitor (DNP) and ligands 1 and 2, namely relatively to the benzylpiperidine moieties. 
The original structure was treated using Maestro v. 9.3 [3] by removing the original 
ligand, solvent, and co-crystallization molecules, and then adding the hydrogen atoms. 
The ligands were built using Maestro, and then, using Ghemical v. 2.0 [4], they were 
submitted to random conformational search (RCS) of 1000 cycles, and 2500 optimization 
steps using Tripos 5.2 force field [5]. The minimized ligands were docked into the AChE 
structure with GOLD software v. 5.1 [6], and the zone of interest was defined as the 
residues within 10 Å from the original position of the ligand in the crystal structure. The 
‘allow early termination’ option was deactivated and the remaining default parameters of 
Gold were used. The ligands were subjected to 100 genetic algorithm steps using ASP as 
fitness function. 
 
2.3. Prediction of pharmacokinetic properties 
To analyze the drug like behavior of the DNP-BIM hybrids, the prediction of their main 
pharmacokinetic properties was performed in silico. This procedure determined 
parameters such as the lipo-hydrophilic character (clog P), blood–brain barrier partition 
coefficient (log BB), the ability to be absorbed through the intestinal tract (Caco-2 cell 
permeability) and CNS activity. 
The ligands were built and minimized as previously mentioned for the docking studies. 
The structures were submitted to the calculation of these relevant pharmacokinetic 
properties and descriptors using QikProp v. 2.5 [7]. These predictions are for orally 
delivered drugs and assume non-active transport. 
 
2.4. Metal chelation studies 
2.4.1. Potentiometric and UV-vis spectrophotometric titrations 
Solutions. The aqueous copper (CuCl2, 0.015 M) and zinc (ZnCl2, 0.0156 M) stock 
solutions for potentiometric and spectrophotometric equilibrium studies were prepared 
from 1000 ppm standards (Titrisol) and their metal content was evaluated by atomic 
absorption. The titrant solution (0.1 M KOH) was obtained from a carbonate-free 
commercial concentrate (Titrisol) and standardized by potentiometric titration with 
potassium hydrogen phthalate. The titrant solution was discarded whenever the 
percentage of carbonate (Gran’s method) [8] was about 0.5% of the total amount of base.  
Measurements. Compound 1 was titrated in 50% (w/w) DMSO/H2O medium, at T = 25.0 
 0.1 °C and ionic strength (I) 0.1 M KCl, by using 0.1 M KOH as titrant. Both glass and 
Ag/AgCl reference electrodes were previously conditioned in DMSO/H2O mixtures with 
increasing amount of DMSO and the response of the glass electrode was controlled by 
strong acid – strong base (HCl/KOH) calibrations with the determination of the Nernst 
parameters by Gran’s method [8]. The measurements were performed in a final volume 
of 30.00 mL, with the ligand concentrations (CL) 6.7  10-4 M (potentiometry) and 4.0  
10-5 M (spectrophotometry), under different CM/CL ratios: 0:1 (L), 1:1 and 1:2 (M = Cu, 
Zn). The spectrophotometric measurements were carried out at pH ca 2.5-11.5, in the 
300–420 nm wavelength range. All titrations were performed in duplicate and under the 
stated experimental conditions the pKw value (13.6) was determined and subsequently 
used in the computations. The stepwise protonation constant of the ligand, Ki = HiL/Hi-
1LH, and the overall metal–complex stability constants, 
lhm LHM
 = 
MmHhLl/MmHhLl, were calculated by fitting the potentiometric and 
spectrophotometric data with, respectively, Hyperquad 2008 [9] and PSEQUAD 
programs [10]. The metal hydrolysis constants were determined under the defined 
experimental conditions (I = 0.1 M KCl, 50% w/w DMSO/H2O, T = 25.0  0.1 °C) and 
the following values of stability constants were included in the fitting of experimental 
data towards the equilibrium models related to the Cu2+/L and Zn2+/L systems: log
22 HCu

= -9.99; log ZnH-2= -14.79, log ZnH-3 = -23.48. Species distribution curves were plotted 
with the Hyss program [9]. 
2.4.2. ESI-MS spectra 
The pH of the Cu(II)/1 (CL = 2.25  10-4 M) and Zn(II)/1 (CL = 2.25  10-4 M) systems 
in 50% w/w DMSO/water medium was previously ascertained to 4.28 (CL/CCu = 1) and 
6.42 (CL/CCu = 2), as well as to 7.01 and 8.39 (CL/CZn = 2), by using KOH solution, and 
the respective mass spectra were obtained from a LCQ Fleet mass spectrometer operated 
in the ESI positive and negative ion mode (Thermo Scientific). The optimized parameters 
were as following: ion spray voltage, +4.5/-2.5 kV; capillary voltage, 16/-28 V; tube lens 
offset, -63 V; sheath gas (N2), 80 arbitrary units; auxiliary gas, 5 arbitrary units; capillary 
temperature, 250 ᵒC. The spectra were recorded in the range 100 – 1000 Da. Spectra 
typically correspond to the average of 20–35 scans. 
2.4.3. EPR spectra 
CW-EPR spectra were recorded with a BRUKER EleXsys E500 spectrometer 
(microwave frequency 9.85 GHz, microwave power 10 mW, modulation amplitude 5 G, 
modulation frequency 100 kHz). Two samples were prepared for each compound (1 and 
2), one at ligand excess and another around equimolar concentration in 50% w/w 
DMSO/water solution. The pH of the Cu(II)/1 (CL = 1.48  10-3 M) system was 
ascertained to 6.75 (CL/CCu = 1) and 6.91 (CL/CCu = 1.5), while that of the Cu(II)/2 (CL = 
2.23  10-3 M) system was to 5.46 (CL/CCu = 1) and 5.72 (CL/CCu = 2), by using KOH 
solution. Room temperature spectra were measured in capillary at 298 K. Anisotropic 
EPR spectra were recorded in quartz EPR tubes immersed in a Dewar containing liquid 
nitrogen (77 K); 0.025 mL MeOH was added to the 0.2 mL sample to avoid water 
crystallization upon freezing. All recorded EPR spectra, and anisotropic EPR spectra at 
77 K, were simulated by the EPR program [11]. To describe the isotropic spectra the 
parameters g0, A0Cu copper hyperfine (ICu= 3/2) and a0N nitrogen (IN = 1) superhyperfine 
couplings have been taking into account. The four copper(II) linewidths were treated with 
individual linewidth parameters. The g-tensor (gx, gy, gz,), copper hyperfine tensor (AxCu, 
AyCu, AzCu) and nitrogen hyperfine tensor (axN,ayN,azN, for wich x y and z denotes the 
directions of the g-tensor) parameters were fitted. For the description of the linewidth the 
orientation dependent  and  parameters were used to set up each component spectra. 
Since a natural copper(II)chloride was used for the measurements, both the isotropic and 
anisotropic spectra were calculated as the sum of the spectra of 63Cu and 65Cu weighted 
by their natural abundances. The hyperfine and super-hyperfine coupling constants and 
the relaxation parameters were obtained in field units (Gauss = 10-4 T). 
 
2.4.4. Molecular modeling of the copper complexes 
In the absence of X-ray structure, a molecular modelling study was performed aimed at 
providing some further insight into the 1:1 (M/L) copper complex structures of 
compounds 1 and 2, considering, respectively, one and two water molecules in the 
coordination shell. These studies were carried out with full geometry optimization of the 
Cu(II) complexes by quantum mechanical calculations based on DFT methods included 
in the Gaussian 03 program software [12] with the B3PW91 hybrid functional. 
Preliminary molecular simulation was obtained by using 3-21G basis set and afterwards 
6-31G**. No symmetry constrains were enforced during geometry optimization with the 
two basis sets. The calculations were performed as well for one water molecule by using 
the B3PW91 functional, first with the 3-21G basis set and subsequently re-optimized via 
6-31G** basis set. Frequency calculations were performed to confirm the nature of the 
minima. The electronic energies (Eb1) obtained at the PBE0/b1 level of theory were 
converted to free energy (Gb1) at 298.15 K and 1 atm by using zero point energy and 
thermal energy corrections based on structural and vibration frequency data calculated at 
the same level.   
 
2.5. Biological studies 
2.5.1. Acetylcholinesterase inhibition 
The enzymatic activity of AChE was determined using an adaptation of Ellman’s method, 
as already described [13,14]. Firstly, a stock solution of AChE was prepared by dissolving 
enzyme 500 U in 10 mL of tris(hydroxymethyl)aminomethane (TRIS) buffer (50 mM, 
pH 8). Then, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer was 
used for further dilution of the enzyme solution therefore obtaining the final working 
solution of AChE. The assay solution consisted of 374 μL of HEPES buffer (50 mM and 
pH 8.0), a variable volume (10–50 μL) of the compound’s stock solution (1 mg/mL of 
MeOH), 476 μL of 3 mM bis(3-carboxy-4-nitrophenyl) disulfide (DTNB), 25 μL of AChE 
stock solution and the necessary amount of methanol to attain the same volume of sample 
mixture in a 1 mL cuvette. After mixing, samples were left to incubate for 15 min and 
then 75 μL of 16 mM acetylthiocholine iodide (AChI) solution was added and 
immediately the reaction was monitored at 405 nm for 5 min. Firstly, enzyme activity was 
determined by measuring the rate of enzymatic reaction in solution by recording 
absorbance (with or without enzyme) at 405 nm. To calculate the percent inhibition of 
AChE, the enzyme activity in the presence of increasing concentrations of the test 
compound, as well as for a blank reaction (methanol without compounds), were measured 
at 405 nm. 
The obtained results were expressed in percentage of inhibition through the Eq. (1): 
           (1) 
Where v1 is the initial reaction rate in the presence of the inhibitor and v0 is the initial rate 
of the control reaction. The curves of inhibition were obtained using a plot of percentage 
of enzymatic inhibition versus inhibitor concentration, and a calibration curve was 
obtained from which the linear regression parameters were obtained. 
2.5.2. Inhibition of self- and Cu2+-mediated Aβ aggregation 
Amongst the methods used to measure the aggregation of Aβ1-42, the assay based on 
Thioflavin T (ThT) is the standard procedure [15,16]. This test is performed with Aβ1-42 
peptide previously prepared by dissolving it in 1,1,1,3,3,3–hexafluoro-2-propanol 
(HFIP), an organic solvent useful to solubilize and monomerize the β–sheet protein 
aggregates and reserve them in the fridge. Films are re-dissolved in an Eppendorf tube 
with a fresh solution of a mixture of CH3CN/Na2CO3/NaOH, to have a stable stock 
solution, and, afterwards, added to an optimized fibrillation phosphate buffer. The 
samples must be prepared using MeOH (1 mg/mL) as a solvent with the specific 
procedure, followed by incubation in a water bath for 24 h at 37°C with gentle shaking. 
After incubation, the samples were added to a 96-well plate (BD Falcon) with 180 µL of 
5 µM ThT in 50 mM glycine-NaOH (pH 8.5) buffer. Blank samples were prepared for 
each concentration in a similar way, devoid of peptide. After 5-min incubation with the 
dye, the ThT fluorescence was measured at 446 nm (excitation) and 485 nm (emission). 
2.5.3. Cell viability and neuroprotection 
SH-SY5Y human neuroblastoma cell line (ATCC-CRL-2266) is grown in Dulbecco’s 
modified Eagle’s medium (DMEM), and were obtained from Gibco-Invitrogen (Life 
Technologies Ltd, UK) with 10% heat inactivated fetal calf serum, containing 50 U/mL 
penicillin and 50 μg/mL streptomycin, under a humidified atmosphere of 95% air- 5% 
CO2 at 37 ºC. Cells were plated at 0.12 × 106 cells/mL for cell viability assay. The tested 
compounds were dissolved in DMSO at a concentration of 50 mM and aliquots were 
stored at -20 °C. We performed a dose-response screening (from 10 μM to 40 μM) in 
order to choose the highest non-toxic concentration. As a result we selected: 20 μM final 
concentrations for compounds 18, 19, 20 and 23; 20 μM final concentrations for 
compound 19; 35 μM final concentration for compounds 21 and 24. The final 
concentration of DMSO in culture media did not exceed 0.05% (v/v) and no alterations 
on cells were observed. The compounds were added to the cell media 1 h before the 
% I = 100−(v1/ v0 x 100)
   
incubation with Aβ1-42 or L-ascorbic acid/ferrous sulfate. Aβ1-42 or L-ascorbic acid/ferrous 
sulfate where incubated alone or with the compound for an additional 24 h. Aβ1-42 was 
prepared as 276.9 μM stock in sterile water and added to the medium at 2.5 μM final 
concentration. Ferrous sulfate was freshly prepared as 0.36 M stock in water and added 
to the medium at 500 μM final concentration. L-Ascorbic Acid was freshly prepared as 
80 mM stock in water and added to the medium at 5 mM final concentration. Aβ1-42 was 
purchased from Bachem (Torrance, CA, USA) and ferrous sulfate and L-ascorbic acid 
from Sigma Chemical Co (St. Louis, MO, USA).  
Cell viability was determined by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) reduction test. In viable cells, the enzyme succinate 
dehydrogenase metabolizes MTT into a formazan that absorbs light at 570 nm. Following 
the cell treatment protocol, the medium was aspirated and 0.5 mL MTT (0.5 mg/mL) was 
added to each well. The plate was then incubated at 37 °C for 1 h 30 min protected from 
light. At the end of the incubation period, the formazan precipitates were solubilized with 
0.5 ml of acidic isopropanol (0.04 M HCl/isopropanol). The absorbance was measured at 
570 nm [17]. Cell reduction ability was expressed as a percentage of untreated control 
cells. 
All data were expressed as mean ±S.E.M. of at least three independent experiments 
performed in duplicates. Statistical analyses were performed using GraphPad Prism 5 
(GraphPad Software, San Diego, CA, USA). Differences between two datasets were 
evaluated by two-tailed unpaired Student’s t test A P – value < 0.05 was considered 
statistically significant. 
 
3. Results and Discussion 
 
3.1. Synthesis of compound 1 
The synthesis of compound 1 involved the synthetic strategy summarized in Scheme 1, 
while the synthesis of compound 2 was previously reported [20]. 
 
 
Scheme 1. Reagents and conditions: i) phthalic anhydride, 160 °C, 4 h; ii)) benzyl 
bromide, K2CO3, triethylamine, acetonitrile, 50 °C, 3 h; (iii) N2H4 xH2O, absolute ethanol, 
reflux, 3 h, then RT, overnight; iv) dimethylacetamide, Na2S2O5, 100°C, 12 h; v) DCC, 
N-hydroxysuccinimide, dry DMF, RT, 24 h.  
 
This involved the synthesis of two main frameworks, a benzyl-piperidine-methanamine 
(1b) and carboxylic derivative of benzimidazole (1c), as well as their attachment through 
an amidic linkage. The preparation of 1b involved a 3-step reaction. Firstly, the the 
primary amine group of the commercially available piperidinemethanamine was 
protected, as a phthalimide group, by reaction with phthalic anhydride, followed by the 
piperidine N-benzylation, by reaction with benzyl bromide in basic conditions, affording 
1a. This was subsequently released from phthalimide group by reaction with hydrazine 
hydrate in absolute ethanol, affording the free amine derivative (1b). Parallely, The 
hydroxyphenylbenzimidazole carboxylic acid (1c) was prepared by Mannich reaction 
between 3,4-diamino benzoic acid and salicylaldehyde and cyclization in the presence of 
the reducing agent sodium metabissulfite [19]. Finally the intermediates 1b and 1c were 
coupled to each other via amide bond formation, affording the novel hybrid 1. This 
reaction was carried out in dry DMF with NHS and DCC as activators, under N2 
atmosphere for two days. 
3.2. Molecular design and modeling studies of ligand-AChE interactions 
DNP is undoubtedly a contemporary choice as anti-AD drug and therefore it was herein 
used as an inspiration to design the new hybrid 1. In this way, N-benzylpiperidine was 
enclosed in the structure of the hybrid and further connected to a hydroxyphenyl-
benzimidazole (BIM) unit. The N-benzylpiperidine portion mimics the binding 
interaction of DNP within the catalytic anionic site (CAS) of AChE [12] while the BIM 
moiety is expected to mimic the indanone segment of DNP in its interaction with the 
peripheral anionic site (PAS) of the enzyme, besides providing additional properties to 
the hybrids, such as anti-Aβ42 aggregation and metal chelating activity [16,17,40,41]. It 
is well known that DNP establishes a strong interaction within the active site of human 
acetylcholine esterase, hAChE, and also of the electric ray homologue (Torpedo 
californica), TcAChE. Notwithstanding some differences between the respective 
inhibitor-enzyme complexes, both enzymes are fairly conservative in terms of the main 
aminoacid residues that coat the active site gorge [42] and so the herein described 
modeling study was performed with TcAChE.  
 
Fig. 2. Superposition of compound 1 (above) and 2 [17] (below) and the original ligand 
(DNP), from PDB code 1EVE, inside the TcAChE active site: DNP (green), compound 1 
(yellow) and compound 2 (brown). 
 
The binding of DNP to TcAChE includes three types of interactions: in the bottom of the 
gorge, the benzyl group establishes a parallel π-π stacking with the indole group of Trp84; 
in the middle of the gorge, the charged nitrogen atom can establish a cation-π binding 
interaction with the phenyl group of Phe330; at the entrance of the gorge, the indanone 
ring interacts through π-π stacking with the peripheral anionic residue Trp279. The 
docking simulations with compounds 1 and 2 show some differences in their 
accommodation inside the gorge of the enzyme, namely concerning the interaction of the 
benzylpiperidine moiety with the aminoacid residues of CAS: in the case of compound 2 
there is an excellent superimposition with the original ligand (DNP), while compound 1, 
thought it can establish identical binding through the piperidine nitrogen atom, it slightly 
deviates from the position of the original ligand (see Fig. 2). On the other way, the BIM 
moieties of both compounds seem to be involved quite similarly in the interactions with 
PAS, allowing a π-π interaction with the indole group from Trp279, although probably 
with a less favorable orientation than DNP. This fact is eventually due to the larger size 
of the BIM unit when compared with that of the indanone group of DNP. Therefore, as a 
conclusion, the modeling studies seem to predict that the ortho compound 1 is a less good 
AChE inhibitor than its positional isomer (compound 2). 
 
3.3. Acid-base properties  
 
The chelating capacity of compound 1, with the BIM unit ortho-attached to the 
benzylpiperazinic moiety, was studied by pH-potentiometric (M = Cu2+, Zn2+) as well as 
ultraviolet-visible (UV-vis in the case of Cu2+ system) spectrophotometric titrations for 
the different M/L systems: 0:1, 1:1 and 1:2.  A 50% w/w DMSO/water medium was 
adopted to perform these studies, due to some solubility problems of the compound. 
Nevertheless, in terms of cellular studies, the amount of ligand used is lower ( 7 M) 
and so the final concentration of DMSO employed in culture media would be even 
inferior ( 1%), therefore not expecting to involve modifications in biological tissues.  
In order to establish the metal chelating model, first the protonation constants of 1 were 
determined by both above referred experimental techniques (see Fig. 1) and the values 
obtained are contained in Table 1.  
  
 
Figure 1 – a) Potenciometric titration curves of compound 1 (C
L
 = 6.7  10
-4
 M) in 50% 
w/w DMSO/water; b) Absorption spectra of 1 (2.56  pH  11.53, C
L
 = 4  10
-5
 M) in 
50% w/w DMSO/water and outset containing the individual calculated spectra by 
PSEQUAD [10]. 
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Table 1 – Stepwise protonation constants of compound 1 and compound 2 for comparison 
purpose, as well as global formation constantsa for their Cu(II) and Zn(II)) complexes (T 
= 25.0  0.1 ºC, I = 0.1 M KCl, 50% w/w DMSO/water) and pMb values.  
Compound MmHhLl log Ki log 
lhm LHCu
  log 
lhm LHZn
  
 
 
 
 
 
 
 
 
 
 
  
 
1 
 
 
 
(011) 
 
(021) 
 
(031) 
 
(111) 
 
(101) 
 
(1-11) 
 
(122) 
 
(102) 
 
(1-12) 
 
pM 
8.98(2)c 
9.00(1)d 
7.78(4)c 
7.11(3)d 
2.86(5)c 
2.38(8)d 
 
 
 
 
 
 
 
 
 
18.96(8)c 
18.864(6)d 
11.71(7)c 
13.08(2)d 
4.44(4)c 
5.12(2)d 
37.27(5)c 
- 
22.18(9)c 
19.18(9)d 
14.64(6)c 
- 
14.3c 
13.9d 
 
 
 
 
 
 
13.81(7)c 
 
- 
 
 
 
26.51(9)c 
 
- 
 
3.77(8)c 
 
6.4c 
 
 
 
 
 
 
2 e 
(011) 
(021) 
(031) 
(111) 
(122) 
(102) 
(1-12) 
 
pM 
8.671(1) 
7.39(1) 
3.21(1) 
 
 
 
 
16.43(4) 
32.13(4) 
17.91(4) 
8.20(6) 
 
10.7 
 
 
 
13.13(3) 
25.24(8) 
9.94(8) 
- 
 
6.3 
a
lhm LHM
 = MmHhLl/MmHhLl; b pM = −log[M] at pH 7.4 (CL/CM = 10, CM = 
10−6 M), c pH-potentiometric data; d UV-vis spectrophotometric data; e ref. [18]. 
 
Compound 1 was isolated in its neutral mono-protonated form (HL, a = 0 in Fig. 1a)) 
after the synthetic procedure, although the fully protonated species corresponds to H3L2+. 
The three protonation constants contained in Table 1 for compound 1 are in accordance, 
as expected, to those previously obtained for compound 2 and correspond to the 
protonation of the phenolic oxygen of the BIM moiety (log K1), then the N-piperidine 
nitrogen atom (log K2) and finally the imidazole nitrogen N(3) of the BIM portion (log 
K3) [18]. The values obtained by both experimental techniques (potentiometry and UV-
vis spectrophotometry) are quite similar for log K1 values but present some discrepancies 
for log Ki (i =2,3), probably due to the fact that the UV-vis spectrophotometric titrations 
have higher experimental errors also since they are not performed in automated manner 
as the potentiometric ones. 
Taking into consideration the outset in Fig. 1b), enclosing the calculated spectra by 
PSEQUAD of the different protonated species for compound 1, it is possible to see that: 
the fully protonated species (H3L
2+) has three absorption maxima at 306, 334 and 343 nm; 
the absorption at 332 nm correspond to both di- and mono-protonated species (H2L
+ and 
HL); the mono-protonated HL and the deprotonated L- species have a large absorption 
band with maximum at ca 373 nm. Moreover, at pH 7.4 and considering CL = 10
-5 M, as 
an attempt to mimic the physiological conditions, the predominant species is: for 
compound 1, H2L
+ (70%) with a contribution of 29% of the neutral HL species; for 
compound 2, the neutral HL (50%) and 48% of H2L
+. Even though the lipo-hydrophilic 
character is not only determined by the molecular charge but also by the ability to 
establish solute-solvent interactions, the existence of the neutral HL species in significant 
concentrations (ca 29-50%) explains the need of using a 50% w/w DMSO/water medium 
in the solution studies. In fact, in particular compound 2 showed to be insoluble for 
inferior % of DMSO content in the DMSO/water mixtures.    
 
3.4. Metal chelation 
3.4.1. Solution equilibrium studies 
 
The existence of a BIM moiety in the structure of potential anti-neurodegenerative drugs 
was already proven to endow the compounds with capacity for hitting several AD targets, 
such as biometal chelation, eventual dual AChE interaction, as well as self- and Cu-
mediated Aβ aggregation [18-20]. Concerning metal chelation, the BIM unity is a 
bidentate moiety and its (N,O) coordination mode implicates a good potential 
coordination towards hard-soft metal ions. The study of the metal chelating properties of 
compound 1, a positional isomer of the already studied compound 2, containing the BIM 
unit ortho-attached to the benzylpiperazinic moiety, will also show the possibility of 
formation of a (N,O,O) metal coordination type involving both the BIM moiety and the 
adjacent carbonyl oxygen atom.  
The chelating ability of compound 1 was studied by using the same experimental 
techniques (potentiometry, UV-vis spectrophotometry) and experimental medium used 
for the titration of the ligand alone (50% w/w DMSO/water). In the following calculations 
for the 1:1 and 1:2 M/L systems (M = Cu, Zn), the log Ki values previously obtained by 
each experimental method will be used in the complexation studies performed by the 
same methodology. Fig. 1a) evidences an alteration in the deprotonation profile of the 
ligand titration curve due to the presence of the metal ion since the curves for the M(II)/L 
systems lye well below that of the ligand for a  -2 (M = Cu) or a  -1 (M = Zn), thus 
supporting the formation of metal complexes with the deprotonated (L-) and mono-
protonated (HL) forms of the ligand with comparative stability order Cu  Zn. The 
potentiometric curves seem to be in accordance with a (N,O) coordination mode, 
involving the BIM moiety of compound 1, as already found for other BIM derivatives 
[18,21]. Table 1 contains the equilibrium models obtained from the fitting analysis of the 
potentiometric curves (M = Cu, Zn) and the UV-vis spectral data (M = Cu).  
 
 
Figure 2 - Spectrophotometric absorption spectra of the 1:2 Cu2+/ 1 system (2.58 < pH < 
11.51, C
L
 = 4.0  10
-5
 M) in 50% w/w DMSO/water and outset and outset containing the 
individual calculated spectra by PSEQUAD [10].  
 
In the obtained metal complex models, MHL and MH2L2 (not found from 1:2 Cu2+/1 
spectral data) correspond to species with the ligand containing one protonated nitrogen 
atom at the piperidine moiety, while ML and ML2 correspond to complexes involving the 
completely deprotonated form of the ligand; MH-1L and MH-1L2 (not found from 1:2 
Cu2+/1 spectral data) are mixed ligand-hydroxo metal complexes. The models obtained 
for Cu2+/1 system from potentiometric and spectrophotometric data (see Table 1) are not 
identical but quite similar. 
The outset of Figure 2 evidences that the calculated spectra (max (, M-1cm-1) at 317 nm 
(9.3  103) and 380 nm (1.5  104)) for both CuHL and CuL complexes are equal, resulting 
from the fact that the coordination core is exactly the same and so the piperidinic nitrogen 
does not contribute to the copper coordination as already found for compound 2 [18]; the 
intensity of the calculated spectrum rises for the CuL2 species, that displays max (, M-
1cm-1) values corresponding to a shoulder at 361 nm (3.2  104) and a band at 374 (3.4  
104) nm. As expected, to the CuH-1L species corresponds also a more intense spectrum 
with a blue shift of the bands relatively to CuHL/CuL (372 nm (1.5  104)), corresponding 
to the formation of a complex that has an additional coordination site occupied by an 
apical water molecule.  
Comparing, the spectral data of the Cu2+/ 1 and Cu2+/2 systems [18], the most striking 
difference relates to the spectra of the CuHL species, with max at 320, 335 and 365 nm. 
The inexistence, in this last case, of a band at 380 nm may point towards the formation of 
a MHL complex with a coordination core more strained in the case of compound 1 than 
for compound 2.  
Figure 3 shows the species distribution curves for the 1:2 Cu(II)/1 and Zn(II)/1 systems 
by using the potentiometric determined model at the used experimental conditions.  
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Figure 3 - Species distribution curves for the 1:2 M/1 systems: a) M = Cu; b) M = Zn (C
L 
= 6.7 10
-4
 M).  
 
Comparison of the metal chelating capacity of compound 1 with that of the already 
studied analogous compound 2 (see Table1) reveals that the pM values (at pH 7.4, CL/CM 
= 10, CM = 10
−6 M) are analogous for zinc but higher for copper, which may point towards 
the possibility of compound 1 having a different copper coordination core, eventually 
including the adjacent carbonyl oxygen atom, with correspondingly higher stability of the 
copper complex with 1. In fact, previous studies on the copper chelation ability of 8-
hydroxyquinoline (HQ, pCu=13.2 in 60% w/w DMSO/water) [22], a commonly known 
stong chelator, reveals that compound 1 presents a slightly higher Cu2+ chelating capacity 
than HQ while compound 2 shows a small reduction. 
To further examine the proposed complexation models, ESI-MS data was also obtained 
from solutions of M/1 (M = Cu, Zn), in 50% w/w DMSO/H2O and 1:1 and 1:2 M/L 
stoichiometric conditions, at specific pH values. The obtained spectra confirmed the 
existence of 1:1 and 1:2 metal complexes (see Table 2 and Figure 4). The ESI-MS 
analysis of a solution of the 1:1 Cu2+/1 system, at pH 4.28 and in the negative mode, 
showed a group of peaks at m/z 571/573, suggesting a characteristic isotopic distribution 
of a [Cu(L-H)Cl2]
- species. However, due to the lower intensity of the signal, a clear fit 
with a calculated isotopic distribution for [(C
27
H
27
N
4
O
2
)CuCl
2
]
-
 was not achieved. 
 
Table 2 – ESI-MS ions for the Cu2+ and Zn2+ complexes of compound 1 in 50% w/w 
DMSO/H2O (1:2 M/L, CL = 2.25  10-4 M). 
Species  pH 
M = Cu 
(m/z) 
M = Zn  
(m/z) 
[M(L-H)Cl2]
- 7.01 - 573.2/575.2/577.1 
[M(L-H)L]+ 6.42 942.2/944.2 - 
[M(L-H)L]+ 8.39 - 943.2/945.2 
L represents the neutral mono-protonated form of compound 1 
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Figure 4 - a) Expanded ESI(+) mass spectrum for the Cu(II)/1 system (C
L
/C
Cu
 = 2, C
L
 = 
2.25  10
-4
 M, pH=6.42) and species distribution curves. The insert shows the theoretical 
isotopic pattern for [(C
54
H
55
N
8
O
4
)Cu]
+
; b) Expanded ESI(-) mass spectrum for the 
Zn(II)/1 system (C
L
/C
Zn
 = 2, C
L
 = 2.25  10
-4
 M, pH=7.01) and species distribution 
curves. The insert shows the theoretical isotopic pattern for [(C
27
H
27
N
4
O
2
)ZnCl
2
]
-
. 
 
Finally, to analyze the copper coordination core of the complexes with compounds 1 and 
2, EPR spectra of these copper systems were obtained, at room temperature and in frozen 
solution together with the calculated EPR spectra of the component species (see Figure 
5). The solution EPR spectra for the studied systems could be mainly described by free 
copper, CuLH and CuL2H2, as well as the ratio of the species agreed well with the 
distribution curves at the selected pH working values. For the systems with compound 1 
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(1:1) in RT solution and 2 in frozen solution, only the CuLH complex or the free copper 
and CuLH could be detected, respectively. In those cases, the 1:2 Cu/L complex was not 
formed. Nevertheless, for compound 1, the frozen solution sample recorded at 1:1 ratio 
showed a dimer species (Cu2L2H2), besides CuLH, which frequently forms for aromatic 
flat ligands by the off-centered parallel stacking interaction of two mono-complexes 
arranged above each other. The frozen solution spectra of the CuLH and CuL2H2 
complexes show well resolved nitrogen splitting, and could be simulated with one 
nitrogen for CuLH and two nitrogens for CuL2H2, in accordance with the involvement of 
one or to BIM chelating cores. The obtained EPR data are collected in Table 3. 
The comparison of the EPR data for the CuLH complexes of compounds 1 and 2 allows 
concluding that the isotropic and anisotropic g values reflect higher ligand field for 
compound 1 than for compound 2, since the g values are lower for compound 1. This 
result supports the already suggested (N,O,O) tridentate coordination mode for compound 
1, with the involvement of the adjacent carbonyl oxygen atom. For the 1:2 copper 
complex of compound 1 it is probable that the second ligand coordinates equatorially with 
its imidazole nitrogen and axially with the phenolate oxygen atom. This coordination 
change agrees with the facts that gz value decreases only 0.01, comparing with the same 
value of the 1:1 complex, and the Az value also declines evidencing an axial coordination 
with small rhombic distortion. 
 
a) 
 
b) 
 
Figure 5 - Measured (black) and calculated (grey) EPR spectra obtained for a) Cu2+/1 1:1 
(pH = 6.75) and 1:1.5 (pH = 6.91); b) Cu2+/2 1:1 (pH = 5.46) and 1:2 (pH = 5.72) systems 
at room temperature (left) and in frozen solution (right).  
 
Table 3 - Isotropic and anisotropic EPR parameters obtained for the Cu2+ complexes with 
compounds 1 and 2a 
 
So, the spectral data collected, namely EPR information, and the callculated equilibrium 
models obtained for compound 1 point towards a chelating core composed by the N(3) 
imidazole and O-phenol atoms of the ligands, excluding the hypothesis of metal 
coordination through the distant nitrogen atom of the piperidine [18], but eventually 
including the adjacent carbonyl oxygen atom in the case of the copper complexes. 
 
3.4.2. Molecular modeling of the copper complexes 
 
In the absence of X-ray structures, a molecular modelling study was accomplished aimed 
at providing some further insight into the 1:1 copper complex structures with compounds 
1 and 2. In that way, a tridentate (N,O,O) coordination mode was considered for 
compound 1, involving one coordinated water molecule, while a bidentate (N,O) 
coordination type was adopted for compound 2 and two coordinated water molecules 
were included in the chelating core. These studies were carried out with full geometry 
optimization of the Cu2+ complexes by quantum mechanical calculations based on DFT 
methods [23] included in the Gaussian 03 program software [12] with the B3PW91 
functional [24]. Geometry optimizations were obtained by using 3-21G basis set [25] for 
all elements, first, and afterwards re-optimized using 6-31G** [26] for the main group 
elements and the Stuttgart–Dresden pseudopotential and associated basis set for Cu (SDD 
[27]). No symmetry constrains were enforced during geometry optimizations. The 
calculations were performed as well for one water molecule by using the B3PW91 
functional, first with the 3-21G basis set and subsequently re-optimized via 6-31G** basis 
set. 
The energy-minimized structures of the copper complexes present a distorted tetrahedral 
square planar four-coordinate configuration for 1 while for 2 corresponds a distorted 
tetrahedral geometry (see Figure 6).  
 
  
 
Figure 6 – DFT-minimized structures of 1:1 copper complexes with compound a) 1 and 
b) 2. Coloring of atoms: Cu light blue, N blue, O red, C grey and H white. 
 
In the obtained modeling simulations, some identical coordination bond distances can be 
found between the two structures for Cu-H2O (2.02-2.05 Å) and Cu-O-phenol (1.86-1.88 
Å), while the Cu-N distance increases somehow from the copper complex with 1 (1.88 
Å) to that with 2 (1.91 Å), probably due to the stronger tridentate coordination established 
in the case of complex with 1, that also involves the adjacent O-carbonyl atom (distance 
Cu-O-carbonyl 1.96 Å). In the case of the complex with compound 1, the distortion in 
relation to a regular square planar geometry is well demonstrated by the coordination 
bond angles (83.6-93.00) and the almost planar geometry as showed by the bond angles 
of O-phenol-Cu-O-carbonyl (173.10) and N-Cu-water (174.80). On the other hand, the 
copper coordination with compound 2 also exhibits a strong distortion from a tetrahedral 
geometry, with coordination bond angles ranging from 82.4 to 99.70.    
Since these two complexes do not have exactly the same number of atoms, comparison 
of complex stability was based on the determination of the free energy difference (G = 
25.6 Kcal/mol) between Cu-1 complex plus one water molecule and Cu-2 molecule. 
Therefore, the calculations show that the copper complex with compound 1 is more stable 
than that with compound 2, which is according to the previously presented solution 
studies. 
 
3.5. Biological activity 
3.5.1. AChE and Aβ aggregation inhbitory activity  
 
Compound 1 under study was assayed for AChE inhibition through a reported method 
[29] and proved to have a quite good activity (IC50 = 9 µM), analogous to that of 
compound 2 (see Table 4), which is supported by the docking simulations. Actually, 
previous studies already revealed that compounds with BIM motif have good AChE 
inhibitory capacity, in low micromolar range [18-20], although presenting higher values 
than the parent compound DNP. Even so, this last fact does not abolish the purpose of the 
suggested drug design since in multifactorial diseases the advantages of using a multi-
target drug can overcome the disadvantage of losing some specific property 
corresponding to a unique target drug. 
 
Table 4 – Biological properties of compounds 1 and 2: inhibition of AChE (Electric eel), 
self-mediated and Cu-induced Aβ1-42 aggregation as well as some predicted 
pharmacokinetic parameters.   
Compound EeAChE 
 (IC50, µM)a 
Aβ aggreg (%)b 
self-med 
Aβ aggreg (%)b 
Cu-ind 
log Pc,d log BBc,e 
1 9  1 38.6 58.9 4.35 -0.64 
2 4.2  0.8f 48.8 69.0 4.39 -0.73 
DNPf 0.026  - - 4.43 0.13 
a mean  SEM (standard error of the mean) of 3 experiments for 50% inhibition of 
electric eel AChE (EeAChE); b Inhibiton of self- and Cu-mediated Aβ1-42 aggregation 
by thioflavin-T fluorescence method; measurements in presence of inhibitor (40 M) 
for 40 M Aβ1-42 and the values are mean of three independent measurements in 
duplicate (SEM  10%); c predicted values using QikProp program, v. 2.5, ref. [7]; d 
octanol/water partition coefficient; e brain/blood partition coefficient; f ref. [28] 
The anti-amyloidogenic capacity of compound 1, in the absence and in the presence of 
copper, was evaluated based on the measurement of the fluorescence emission of 
Thioflavin T (ThT) associated to fibril binding [15,16]. Due to solubility problems of 
compound 1 in the phosphate buffer (0.215 M, pH 8.0) working medium, the assays were 
accomplished in the presence of 40 M concentration of inhibitor, instead of 80 M 
[18,20], and so the same procedure was adopted for compound 2 for comparison reasons 
(see Table 4). The obtained data show that both compounds induce a decrease on the ThT 
fluorescence associated with Aβ fibril binding. In fact, they inhibit the Aβ1-42 self-
aggregation process with good capacity, slightly higher for the positional isomer 2 than 
for compound 1, probably due to conformational reasons in the ligand intercalation 
between the Aβ fibrils.  In terms of the inhibition of Cu-induced Aβ aggregation, the 
compounds induce an analogous increase (20.2-20.3%) when comparing with their 
corresponding capacity for self-inhibition, in accordance with their good chelating 
capacity towards copper. Nevertheless, these chelators have conditional dissociation 
constants (K´d) for the copper complexes at pH 7.4 of 254 picomolar (1) and 34 nanomolar 
(2), these values being outside the proposed range K´d = 1-10 picomolar corresponding to 
chelators eventually able to retrieve copper from Aβ peptide (K´d = 10 picomolar – 100 
nanomolar for Cu(Aβ) complexes) [30]. In this way, there is no competition for copper 
between these BIM hybrids and Aβ peptide, the inhibition process being apparently 
mainly due to ligand intercalation between the β-sheets of Aβ fibrils.  
In order to assess the potential of compound 1 as an eventual drug, some indicators of its 
pharmacokinetic profiles were calculated with QikProp program [7]. Parameters such as 
the lipo-hydrophilic character (log P), the ability to cross the blood-brain barrier (log BB), 
the ability to be absorbed through the intestinal tract to the blood (Caco-2 cell 
permeability), and the verification of Lipinski’s rule of five, can give an idea of its 
druglikeness for oral administration as an anti-AD drug. Both the positional isomers have 
the same molecular weight (440.5) lower than 500 and present similar lipo-hydrophilic 
character and no violations of the Lipinski´s rule,`s, although the slightly higher values 
for log P, log BB and caco permeability can be responsible for the  slightly better CNS 
activity predicted for the isomer 1 as compared with 2. In summary, both positional 
isomers present good BBB permeability (log BB) and can be eligible as drug candidates 
for oral administration. 
 
Table 5 - Pharmacokinetic properties as predicted in silico by software QikProp v.2.5[7]. 
Comp. MW  
(Da) 
clog P log BB 
Caco-permeability  
(nm/s) 
CNS 
Violations of  
Lipinski’s rule 
1 440.54 4.352 -0.638 225 +/- 0 
2 440.54 4.386 -0.730 194 - 0 
 
 
3.5.2. Cell viability and neuroprotection 
Using neuroblastoma SHSY-5Y cells the potential therapeutic effect of compound 1 was 
tested exposing these cells to Aβ1–42 peptides. For this new compound 1 a dose–response 
curve was performed to select a nontoxic concentration in order to analyze the 
neuroprotective effect (Fig. S2). It was observed that Aβ1–42 induced a decrease in cell 
viability and, interestingly, compound 1 completely prevented Aβ1–42 cellular toxicity, 
as cells present relative viability values comparable to untreated cells (see Fig. 10). In 
opposition, cells treated with Fe/Ascorbate have a decrease in cell viability which 
compound 1 could not prevent. These results demonstrate that the ortho-positional isomer 
(1) has a higher neuroprotective role than the positional isomer 2 [17], and thus a higher 
specificity against Aβ-induced cell toxicity. 
 
4. Conclusions 
A new DNP-BIM hybrid (compound 1), with the BIM unit orthoattached to the 
benzylpiperazinic moiety, was synthesized and studied with the aim of evaluating the 
effect of the imposed structural modification over its physico-chemical and biological 
properties as potential anti-AD drug, in comparison with a previously developed 
positional isomer (compound 2). Compound 1 was found to have a higher chelating 
capacity towards Cu2+ (pCu = 14.3, pZn = 6.4, pH 7.4, CL/ CM = 10, CM = 10−6 M) 
than compound 2 (pCu = 10.7, pZn = 6.3), due to the 1-order increasing of denticity, that 
allows the formation of a (N,O,O) coordination core for Cu2+, as proved by EPR and 
molecular modeling data of the copper complexes. Concerning the biological properties, 
both compounds present good AChE inhibition (low micromolar range), in accordance 
with the docking studies, and are moderate/good inhibitors of Aβ self- and Cu-mediated 
aggregation. Since there is no competition for copper between these BIM hybrids and Aβ 
peptide, the inhibition process appears to be mainly due to ligand intercalation between 
the β-sheets of Aβ fibrils. Therefore, the herein compiled data allows concluding that 
afterapplying a structural change over the already studied compound 2, for the sake of 
increasing ligand denticity and thus improving the metal chelating capacity as well as the 
control/modulation of interconnected multiple pathological aspects of AD, the obtained 
compound 1 presents quite analogous AChE and Aβ self- and Cu-mediated aggregation 
inhibitory capacity, being also eligible as drug candidate for oral administration and with 
improved neuroprotective role against Aβ-induced cell toxicity. 
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